drugset / Trial / NCT05851014
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy
Timeline
- Start
- 2022-01-14
- Primary completion
- 2026-01-30
- Completion
- 2027-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GB491 | Unknown | 150 mg | Oral |
| Background | Letrozole | Other / unclassified | 2.5 mg | Oral |